Skip to main content

Table 2 Investigator-assessed BORR (efficacy-evaluable patients) comparing BCCNS and non-BCCNS patient groups

From: Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials

 

Erivance BCC (N = 96)

EAS (N = 95)

 

laBCC

mBCC

laBCC

mBCC

 

BCCNS

(n = 21)

Non-BCCNS

(n = 42)

Non-BCCNS

(n = 33)

BCCNS

(n = 12)

Non-BCCNS

(n = 44)

BCCNS

(n = 6)

Non-BCCNS

(n = 33)

BORR, n (%)

[95 % CI]

17 (81)

[58–95]

21 (50)

[34–66]

15 (46)

[28–64]

4 (33)

[10–65]

22 (50)

[35–65]

3 (50)

[12–88]

9 (27)

[13–46]

 Complete response

8 (38)

12 (29)

0

1 (8)

5 (11)

2 (33)

0

 Partial response

9 (43)

9 (21)

15 (46)

3 (25)

17 (39)

1 (17)

9 (27)

 Stable disease

3 (14)

12 (29)

15 (46)

6 (50)

21 (48)

3 (50)

17 (52)

 Progressive disease

1 (5)

5 (12)

2 (6)

2 (17)

0

0

3 (9)

 Not evaluable or missing

0

4 (10)

1 (3)

2 (17)

1 (2)

0

4 (12)

  1. BCCNS basal cell carcinoma nevus syndrome, BORR best overall response rate, CI confidence interval, EAS expanded access study, laBCC locally advanced basal cell carcinoma, mBCC metastatic basal cell carcinoma